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Background
Sepsis and septic shock are associated with high mortality
rates and the majority of sepsis patients die due to compli-
cations of multiple organ failure (MOF). The cyclic GMP
(cGMP) producing enzyme soluble guanylate cyclase
(sGC) is crucially involved in the regulation of (micro)vas-
cular homeostasis, cardiac function and, consequently,
organ function. However, it can become inactivated when
exposed to reactive oxygen species (ROS). The resulting
heme-free sGC can be reactivated by the heme- and nitric
oxide (NO)-independent sGC activator BAY 58-2667
(Cinaciguat).
Results
We report that late (+8h) post-treatment with BAY
58-2667 in a mouse model can protect against lethal endo-
toxic shock. Protection was associated with reduced
hypothermia, circulating IL-6 levels, cardiomyocyte apop-
tosis, and mortality. In contrast to the beneficial effect of
BAY 58-2667, the sGC stimulator BAY 41-2272 and the
phosphodiesterase 5 inhibitor Sildenafil did not have any
beneficial effect on survival, emphasizing the importance
of the selectivity of BAY 58-2667 for diseased vessels and
tissues. Hemodynamic parameters (blood pressure and
heart rate) were decreased, and linear and nonlinear
indices of blood pressure variability, reflective for (un)cou-
pling of the communication between the autonomic
nervous system and the heart, were improved after late
protective treatment with BAY 58-2667.
Conclusion
In conclusion, our results demonstrate the pivotal role of
the NO/sGC axis in endotoxic shock. Stabilization of
sGC function with BAY 58-2667 can prevent mortality
when given in the correct treatment window, which
probably depends on the dynamics of the heme-free sGC
pool, in turn influenced by oxidative stress. We speculate
that, considering the central role of sGC signaling in
many pathways required for maintenance of (micro) cir-
culatory homeostasis, BAY 58-2667 supports organ func-
tion by recoupling inter-organ communication pathways.
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